Sona BLW reported a 47 percent YoY increase in consolidated net profit at Rs 112 crore in the June quarter. Brokerages say it'll be difficult to sustain the performance in the long run due to scale disadvantage and pricing pressure
Revenue witnessed an 18-percent growth year-on-year at Rs 639 crore versus Rs 541 crore in the same quarter of last year. The gross profit margins improved for another consecutive quarter to 56.8 percent.
Sales also fell 4 percent year-on-year to Rs 311 crore in the April-to-June quarter. Low sales were due to fewer wedding dates in Q1FY24.
The earnings before interest, taxes, depreciation and amortization (EBITDA) grew by 10.6 percent YoY at Rs 74.1 crore as against Rs 67 crore. However, the EBITDA margin witnessed contraction at 15.9 percent in Q1 FY24 against 17.8 percent in the same period previous year.
The underwater vehicle has been designed to operate in autonomously manner and its design enables it to carry out a variety of roles depending on the payload, the company has said
The record date for determining the shareholders eligible for the rights issue is August 2. The issue will close on August 16
Operating margin shrunk to 15.40 percent from 20.66 percent a year ago, weighed by a surge in other expenses and higher depreciation and amortisation expenses.
In the June quarter, the defence PSU's order book stood at Rs 65,400 crore, up 18 percent YoY, Morgan Stanley said. The order book implies 3.7 times FY23 revenue, which provides strong revenue visibility, ICICI Securities has said.
Indian Hotels stock has given a return of 31.50 percent over the last six months.
The company reported its best ever first quarter pre-sales performance at Rs 3,353 crore alongside a “very strong” business development of Rs 12,000 crore.
Nuvama Institutional Equities has upgraded its rating on Shriram Finance from 'hold' to 'buy' and raised the target price to Rs 2,145
Post the acquisition, Lemon Tree Hotels holds a 59-percent stake in Fleur Hotels, and the rest is held by APG Strategic Real Estate Pool N V.
Revenue from operations also declined to Rs 1,216 crore in the June 2023 quarter, as against Rs 1,240 crore in the year-ago quarter.
The acquisition is in line with the strategy of Welspun Enterprises to grow the water infrastructure business segment. This will enable its entry into the tunnelling business, which complements its existing water and road business.
On July 14, the company's subsidiary, Lupin Inc., based in Somerset, New Jersey, received USFDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg.
JS Auto Cast Foundry India plans to pick a 26 percent stake in Ratnakar Energy Private Limited, which is engaged in power generation. The acquisition is for the purchase of solar power
Laurus Labs registered an EBITDA margin of 14.1 percent in April-June, the lowest-ever on a quarterly basis.
Ajanta Pharma's growth in Q1 was driven by double digit increase in sales from the India and US generics segments.
FIIs have withdrawn around $2.12 billion from the information technology sector, so far, in 2023 amid a challenging demand environment. Mutual funds, however, increased stakes in some midcap IT companies in the June quarter
Stocks to watch: Check out the companies making headlines before the opening bell today, July 27, 2023.
Netweb shares closed with 82 percent rally at Rs 910.40 on its debut despite correction in equity markets.
The market ended lower, with the 30-pack Sensex closing at 66,266.82, down 0.66 percent, and the Nifty declining 0.60 percent at 19,659.90. About 1,746 shares advanced, 1,710 declined and 134 remained unchanged
The company’s net profit rose nearly 23 percent QoQ to Rs 137.5 crore as compared to Rs 112.2 crore a quarter ago. Whereas revenue rose 3 percent to Rs 1,262.7 crore. Operating margin also expanded by 168 bps sequentially to 15.3 percent.
The company's board is scheduled to meet on July 28, to consider, approve and take on record standalone and consolidated unaudited financial results of the company for the quarter ended on June 30
The plerixafor injection, used by patients with certain types of cancer to prepare them for a stem cell transplant, will be manufactured at the group’s facility in Ahmedabad